News

LBT Innovations @ ExchangeSA
Today our managing director and CEO presented at the ExchangeSA 2019 listed companies conference in Adelaide
MRSA Analysis Module CE Mark Registration
We are pleased to announce that the Declaration of Conformity for the APAS® MRSA analysis module has been completed.
Finance News Network Interview with Brent Barnes
Brent Barnes, talks FY19 results and outlook and the adoption of our culture plate reading device APAS,, the sales process and regulatory approval.
ASX Small and Mid-Cap Conference 2019
LBT's CEO and Managing Director Brent Barnes presenting at the ASX Small and Mid-Cap Conference in Sydney on the 5th of September 2019
Proactive Investors Interview with Brent Barnes
Brent Barnes updates Proactive Investors on developments to forge ahead with product sales of its unique APAS Independence technology. 
LBT Presentation, FNN Investor Event
Our CEO presents on LBT's automated plate reading device for use in laboratories, regulatory clearance in the US and the size of the market opportunity.
APAS® INDEPENDENCE US FDA 510(k) CLEARANCE
A historic day as APAS Independence with Urine Analysis Module is available for sale in the United states providing access to over 1,500 potential customers.
Bioshares Analyst Report
LBT Innovations is resetting expectations with investors regarding the sale process for its automated plate processing instrument, called APAS Independence. Read the full report here.
MRSA Analysis Module – Clinical Study Commenced
We are pleased to announce that we have commenced a clinical study to validate clinical performance of APAS Independence’s automatic analysis of MRSA.
Breaking Into The US Market. What Does It Really Take? 
Our VP of Global Business Development Peter Bradley recently presented at the ANDHealth Digital Health Summit in Melbourne
Appointment US Based Non-Executive Director: Simon Arkell
LBT Innovations is pleased to announce the appointment of Simon Arkell as a Non-Executive Director, starting 30th January 2019.
FDA 510(k) submitted for APAS® Independence
LBT Innovations joint venture company, Clever Culture Systems submits US FDA 510(k) for APAS Independence instrument with Urine Analysis Module.
Australian Sales Update
LBT Innovations provides an update on sales activities in the Australian market and previously advised expected sales of the APAS® Independence in calendar 2018.
First Placement of APAS Independence into US Lab
Clever Culture Systems has placed the first APAS® Independence into a US medical centre to act as a key opinion leader ahead of US commercial launch.
First sale of APAS Independence
PAC Partners Analyst Report - Analyst report from PAC Partners following the first sale of APAS Independence to St Vincent's Hospital in Melbourne
Quarterly Activities & Cashflow Report
We are pleased to release our Quarterly Cashflow report and Update for the quarter ended 30 September 2018 (the Quarter).